Active Ingredient History
Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Ticlopidine is a prodrug that is metabolized to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significance in vitro activity at the concentrations attained in vivo. The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. Ticlopidine is FDA approved for the prevention of strokes and, when combined with aspirin, for patients with a new coronary stent to prevent closure. There are also several off-label uses, including acute treatment of myocardial infarction and unstable angina, peripheral vascular disease, prevention of myocardial infarctions, diabetic retinopathy, and sickle cell disease. The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Coronary Artery Disease (approved 1991)
Stroke (approved 1991)
Angina, Stable (Phase 3)
Antiphospholipid Syndrome (Phase 4)
Atrial Fibrillation (Phase 4)
Cardiovascular Diseases (Phase 4)
Carotid Stenosis (Phase 3)
Cerebral Infarction (Phase 4)
Cerebrovascular Disorders (Phase 4)
Coronary Artery Disease (Phase 4)
Dry Eye Syndromes (Phase 3)
Healthy Volunteers (Phase 1)
Hemorrhage (Phase 4)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Myocardial Infarction (Phase 3)
Peripheral Arterial Disease (Phase 3)
Pharmacokinetics (Phase 4)
Stroke (Phase 4)
Thrombosis (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
